Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

RYTARY ER 61.25 MG-245 MG CAP

Carbidopa and Levodopa
$4.9945per EA
High Outlier

Strength

61.25; 245 mg/1; mg/1

Manufacturer

Amneal Pharmaceuticals LLC

NDC

64896066401

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

CARBIDOPA HYDRATE; LEVODOPA

Approval Type

New Drug (NDA)

FDA Application

NDA203312

On Market Since

1/12/2015

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid

Price History

1W

0.0%

1M

+0.0%

3M

+0.0%

6M

-0.1%

1Y

-0.3%

3Y

+0.2%

5Y

+18.9%

All

+78.9%

Generic Alternatives

Save up to 30%

2 alternatives • Same active ingredient

RYTARY ER 61.25 MG-245 MG CAP
Brand
64896066443•Amneal Pharmaceuticals LLC
$3.5009
Save 30%
CARBIDOPA-LEVO ER 61.25-245 CP
Generic
70710214201•Zydus Pharmaceuticals (USA) Inc.
$3.7464
Save 25%

Related Drugs

Same classification

SINEMET 25-100 MG TABLET
Brand
78206016801•Organon LLC
$1.4236
per EA
SINEMET 25-100 MG TABLET
Brand
78206019001•Organon LLC
$1.4236
per EA
DHIVY 25-100 MG TABLET
Brand
75854070101•Avion Pharmaceuticals, LLC
$3.6141
per EA
CREXONT ER 87.5 MG-350 MG CAP
Brand
64896097016•Amneal Pharmaceuticals LLC
$4.3618
per EA
CREXONT ER 70 MG-280 MG CAP
Brand
64896096916•Amneal Pharmaceuticals LLC
$4.3622
per EA
CREXONT ER 52.5 MG-210 MG CAP
Brand
64896096816•Amneal Pharmaceuticals LLC
$4.3643
per EA
CREXONT ER 35 MG-140 MG CAP
Brand
64896096716•Amneal Pharmaceuticals LLC
$4.3692
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy